New Oral Anticoagulants: “everyday clinical practice” experience

Pedro Abreu1,2

1Neurology Department, Centro Hospitalar de São João, Porto, Portugal
2Department of Clinical Neurosciences and Mental Health, Faculdade de Medicina da Universidade do Porto, Portugal

Abstract

Introduction: New oral anticoagulants (NOACs) were shown, when compared to warfarin in a randomized controlled trial setting, to be effective in reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients.

Objectives: This presentation will assess, with special emphasis on rivaroxaban, efficacy, safety and persistence/adherence in an “everyday clinical practice” population of drug-naïve NVAF patients treated with NOACs.

Methods: A PubMed® database non-systematic search of the latest articles published on efficacy, safety and persistence/adherence outcomes of NOACs as used in “everyday clinical practice” was performed.

Results: Efficacy, safety and persistence/adherence outcomes of NOACs in an “everyday clinical practice” population of drug-naïve patients with AF were consistent with the results of previous randomized controlled trials across a wide range of “real life” patients.